You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Multiple myeloma asymptomatic relapse symptomatic relapse

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Biological Relapse in Patients With Multiple Myeloma

Terminated
  • Multiple Myeloma
    • Zaragoza, Aragón, Spain
    • +43 more
    Sep 7, 2021

    Selinexor, Daratumumab and Dexamethasone in Chinese Multiple

    Not yet recruiting
    • Multiple Myeloma at First Relapse
      • (no location specified)
      Sep 27, 2022

      Multiple Myeloma Trial in Houston (Belantamab mafodotin)

      Recruiting
      • Multiple Myeloma
      • Belantamab mafodotin
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 5, 2023

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Oct 30, 2023

      Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

      Not yet recruiting
      • Refractory Multiple Myeloma
      • +2 more
      • Boston, Massachusetts
      • +2 more
      Nov 17, 2023

      Multiple Myeloma, Allogeneic Stem Cell Transplantation Trial in Spain (CARTemis-1)

      Not yet recruiting
      • Multiple Myeloma
      • Allogeneic Stem Cell Transplantation
      • CARTemis-1
      • Santander, Cantabria, Spain
      • +4 more
      Aug 1, 2023

      Multiple Myeloma Trial in Hamburg (allogeneic HSCT)

      Completed
      • Multiple Myeloma
      • allogeneic HSCT
      • Hamburg, Germany
        University Medical Center Hamburg-Eppendorf
      Sep 1, 2022

      Multiple Myeloma in Relapse Trial in Shenzhen (BCMA/GPRC5D double CAR-T)

      Recruiting
      • Multiple Myeloma in Relapse
      • BCMA/GPRC5D double CAR-T
      • Shenzhen, Guangdong, China
        Shenzhen Qianhai Shekou Free Trade Zone Hospital
      Sep 28, 2023

      Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

      Not yet recruiting
      • Multiple Myeloma
      • Multiple Myeloma in Relapse
      • Belantamab mafodotin, Venetoclax
      • (no location specified)
      May 10, 2023

      Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

      Not yet recruiting
      • Multiple Myeloma, Refractory
      • Multiple Myeloma in Relapse
      • Autologous CAR-T cell therapy expressing the BAFF-ligand.
      • Cleveland, Ohio
        University Hospitals Seidman Cancer Center
      Jan 11, 2023

      Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

      Recruiting
      • Relapse/Refractory Multiple Myeloma
      • DeepTag-GPRC5D Targeted CAR T-cells
      • Hangzhou, Zhejiang, China
        The first affiliated hospital of medical college of zhejiang uni
      Oct 10, 2023

      Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • Relapse Multiple Myeloma
      • Belantamab mafodotin
      • +3 more
      • Chicago, Illinois
        University of Chicago Medicine Comprehensive Cancer Center
      Mar 23, 2023

      Health Technology Intervention on Patient Activation in Multiple

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • +3 more
        • (no location specified)
        Jan 9, 2023

        Learn How Triple Class Refractory Multiple Myeloma Are Treated

        Not yet recruiting
        • Relapse Multiple Myeloma
        • Refractory Multiple Myeloma
          • (no location specified)
          Feb 15, 2023

          Multiple Myeloma Trial in Cologne (Daratumumab)

          Recruiting
          • Multiple Myeloma
          • Cologne, Germany
            University of Cologne
          Apr 4, 2022

          Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

          Recruiting
          • Multiple Myeloma in Relapse
          • Aurora, Colorado
            University of Colorado Hospital
          Jan 31, 2023

          Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

          Recruiting
          • Relapsed and/or Refractory Multiple Myeloma
          • Plasma Cell Leukemia in Relapse
          • Biological
          • Shanghai, Shanghai, China
            Shanghai Tongji Hospital
          May 29, 2023

          MMRR Treated With Belantamab Mafotidine on Monotherapy

          Not yet recruiting
          • Multiple Myeloma
          • Belantamab mafodotin
          • (no location specified)
          May 23, 2022

          Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

          Not yet recruiting
          • Multiple Myeloma in Relapse
          • Multiple Myeloma, Refractory
          • Anti-GPRC5D CAR-T Cells Injection
          • (no location specified)
          Feb 18, 2023

          Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

          Not yet recruiting
          • Multiple Myeloma in Relapse
          • Multiple Myeloma, Refractory
          • (no location specified)
          Jun 8, 2023

          Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

          Not yet recruiting
          • Multiple Myeloma
          • +4 more
          • Chapel Hill, North Carolina
          • +2 more
          Jun 9, 2023

          Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

          Active, not recruiting
          • Multiple Myeloma in Relapse
          • Multiple Myeloma, Refractory
          • Poitiers, France
            CHU Poitiers
          Jan 9, 2023

          Multiple Myeloma in Relapse Trial in Paris (Daratumumab/Lenalidomide/Dexamethasone for 24 months,

          Recruiting
          • Multiple Myeloma in Relapse
          • Daratumumab/Lenalidomide/Dexamethasone for 24 months
          • Daratumumab/Lenalidomide/Dexamethasone until progression
          • Paris, France
            Saint Antoine Hospital - Hematology Department
          Jun 10, 2022

          Multiple Myeloma, Relapse Multiple Myeloma Trial in Bethesda, Madison (Descartes-25)

          Recruiting
          • Multiple Myeloma
          • Relapse Multiple Myeloma
          • Shreveport, Louisiana
          • +3 more
          Nov 4, 2022

          Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

          Not yet recruiting
          • Multiple Myeloma in Relapse
          • Multiple Myeloma, Refractory
          • (no location specified)
          Aug 8, 2022